Y-mAbs Therapeutics, Inc. (YMAB) Financials

YMAB Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 127.9 million 26.9 million
2023-09-30 128.9 million 28.7 million
2023-06-30 132.4 million 27.7 million
2023-03-31 137.4 million 29.6 million

YMAB Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -8.0 million 3.1 million
2023-09-30 -1.3 million 2.4 million
2023-06-30 -4.7 million 3.6 million
2023-03-31 -13.1 million 5.3 million

YMAB Net Income

No data available :(

YMAB Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 78.6 million - 1.4 million
2023-09-30 86.6 million - 1.6 million
2023-06-30 87.9 million - 1.2 million
2023-03-31 92.6 million - 1.5 million

YMAB Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 43.6 million
2023-09-30 43.6 million
2023-06-30 43.7 million
2023-03-31 43.7 million

YMAB Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 13.4 million 11.1 million -
2023-09-30 - 15.4 million 10.2 million -
2023-06-30 - 12.1 million 11.3 million -
2023-03-31 - 13.4 million 12.3 million -

YMAB Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 23.4 million 2.0 million
2023-09-30 20.5 million 2.6 million
2023-06-30 20.8 million 4.6 million
2023-03-31 20.3 million 2.1 million

YMAB

Price: $17.28

52 week price:
4.60
20.90

Earnings Per Share: -0.49 USD

P/E Ratio: -29.09

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 294900

Market Capitalization: 629.1 million

Links: